Difference between revisions of "RhoA"
m |
m |
||
Line 51: | Line 51: | ||
| Q63 is deamidated/transamidated by TG2 | | Q63 is deamidated/transamidated by TG2 | ||
− | The transamidated protein has increased binding affinity to ROCK-2. The deamidated form (by cytotoxic dermonecrotizing factor or BTX) has decreased GTPase activity. | + | The transamidated protein has increased binding affinity to ROCK-2. |
+ | The deamidated form (by cytotoxic dermonecrotizing factor or BTX) has decreased GTPase activity. | ||
+ | |- | ||
+ | |Video | ||
+ | |{{#ev:dailymotion|19dSThNNq2NLtkXZ8|300}} | ||
|- | |- | ||
| {{infobox header}} | | | {{infobox header}} | |
Revision as of 13:21, 14 September 2007
Template:Infobox header| RhoA | |
---|---|
Substrate peptide name | RhoA |
Synonyms | - |
Determination type | In situ/In vitro |
Source | Homo sapiens |
Subcellular localization | Cytoskeleton |
Swissprot ID | P61586 |
Reactive glutamines | Q52, Q63, Q136 |
Reactive lysines | - |
Substrate sequence | EVDGKQVELAL
WDTAGQEDYDR LAKMKQEPVKP |
Structure | 1A2B |
Surface accessibility | ASAView pdf
ASAView txt |
Disorder prediction | IUPred |
Reference | PMID:9593707 |
Notes | Q63 is deamidated/transamidated by TG2
The transamidated protein has increased binding affinity to ROCK-2. The deamidated form (by cytotoxic dermonecrotizing factor or BTX) has decreased GTPase activity. |
Video | 19dSThNNq2NLtkXZ8|300}} |
Template:Infobox header | |